Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395992 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT01395992 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 165 participants.
The verdict
NCT01395992, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
Participants who have completed the 3-week trial P05691 (NCT00764478) can be screened for eligibility for this 26-week extension study in which they will continue treatment. The primary purpose of this trial is to evaluate the long-term safety of asenapine.
Interventions
- DRUG asenapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395992
The ClinicalTrials.gov registry entry for NCT01395992 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which asenapine is the first listed.
NCT01395992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395992 about?
NCT01395992 is a clinical study titled "Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)". Participants who have completed the 3-week trial P05691 (NCT00764478) can be screened for eligibility for this 26-week extension study in which they will continue treatment. The primary purpose of this trial is to evaluate the long-term safety of asenapine.
What is the current status of trial NCT01395992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2012-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01395992?
The interventions under investigation include: asenapine (DRUG).
Who is sponsoring clinical trial NCT01395992?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.